Madrigal Pharmaceuticals stock price target raised by Oppenheimer on patent news

Madrigal Pharmaceuticals (MDGL) received a price target increase from Oppenheimer to $500 from $475, maintaining an Outperform rating, following a critical patent extension for its MASH drug, Rezdiffra. The USPTO's Notice of Allowance extends Rezdiffra's market exclusivity to Q3 2044, providing over 10 additional years of protection from generic competition, which Oppenheimer expects will significantly strengthen the company's valuation and long-term growth prospects, complementing Rezdiffra's strong U.S. launch and European approval progress.

Analysis

Madrigal Pharmaceuticals (MDGL) has secured a significant long-term competitive advantage with the U.S. Patent and Trademark Office's Notice of Allowance for its MASH treatment, Rezdiffra. This development extends the drug's market exclusivity by over a decade to the third quarter of 2044, a material change from the previous 2033 expiration. This extended protection horizon prompted Oppenheimer to revise its financial model and raise its price target to $500 from $475, reinforcing its Outperform rating. The positive outlook is further substantiated by strong operational performance, as Rezdiffra's U.S. launch has already surpassed expectations with sales beating consensus and over 17,000 patients onboarded last quarter. Additionally, the path to European market entry appears clear following a positive recommendation from the EMA's Committee for Medicinal Products for Human Use, with a final decision anticipated by August 2025. These factors, combined with continued bullish sentiment from firms like Citizens JMP, solidify Rezdiffra's position as a first-in-class treatment with a newly fortified, long-duration revenue stream.

Key Decisions for Investors

• The patent extension to 2044 materially enhances Rezdiffra's long-term discounted cash flow valuation, suggesting that investors with a long-term growth focus may find the stock's fundamental case significantly strengthened.
• Investors should monitor key upcoming catalysts, including the final European approval decision expected in August 2025 and the results from a forthcoming comparative analysis against other treatments, both of which could impact future market share and revenue projections.
• Given that the stock's valuation is heavily dependent on Rezdiffra's success, it is critical to track quarterly U.S. prescription and sales data to ensure the strong initial launch momentum is sustained.